Mingkun Jiao, Gang Liu, Yu Xue and Chunyong Ding Pages 767 - 775 ( 9 )
Due to ever-increasing failure rates, high cost, unsatisfactory safety profile, and limited efficacy associated with anticancer drug development, the repositioning of established non-cancer drugs for new oncology indications has emerged as an increasingly attractive approach to addressing the unmet cancer-related medical need. With the rapid development of bioinformatics, chemoinformatics as well as high-performance computing, drug repositioning is becoming more intentional than ever, and a significant surge of computational approaches has been well established to greatly facilitate drug repositioning for cancer treatment. In this review, we provide a brief overview of recent advances in the computational drug repositioning for anticancer applications with a specific emphasis on repositioning of non-cancer drugs by use of various computational approaches.
Anticancer drugs, Cancer therapeutics, Computational drug repositioning, Drug discovery, Drug repositioning, Drug repurposing.
Shanghai Institute of Materia Medica (SIMM), 555 Zu Chong Zhi Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, China 201203.